Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,790 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers.
Hultcrantz M, Richter J, Rosenbaum C, Patel D, Smith E, Korde N, Lu S, Mailankody S, Shah U, Lesokhin A, Hassoun H, Tan C, Maura F, Derkacs A, Diamond B, Rossi A, Pearse RN, Madduri D, Chari A, Kaminetsky D, Braunstein M, Gordillo C, Davies F, Jagannath S, Niesvizky R, Lentzsch S, Morgan G, Landgren O. Hultcrantz M, et al. Among authors: patel d. medRxiv [Preprint]. 2020 Jun 11:2020.06.09.20126516. doi: 10.1101/2020.06.09.20126516. medRxiv. 2020. Update in: Blood Cancer Discov. 2020 Jul 30;1(3):234-243. doi: 10.1158/2643-3230.BCD-20-0102 PMID: 32577667 Free PMC article. Updated. Preprint.
Oncologic immunomodulatory agents in patients with cancer and COVID-19.
Jee J, Stonestrom AJ, Devlin S, Nguyentran T, Wills B, Narendra V, Foote MB, Lumish M, Vardhana SA, Pastores SM, Korde N, Patel D, Horwitz S, Scordo M, Daniyan AF. Jee J, et al. Among authors: patel d. Sci Rep. 2021 Mar 1;11(1):4814. doi: 10.1038/s41598-021-84137-5. Sci Rep. 2021. PMID: 33649382 Free PMC article.
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Piedra K, Peterson T, Tan C, Orozco J, Hultcrantz M, Hassoun H, Mailankody S, Lesokhin A, Shah U, Lu S, Patel D, Derkach A, Wilkins CR, Korde N. Piedra K, et al. Among authors: patel d. Br J Haematol. 2022 Jan;196(1):105-109. doi: 10.1111/bjh.17772. Epub 2021 Aug 15. Br J Haematol. 2022. PMID: 34396516 Free PMC article.
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.
Hultcrantz M, Richter J, Rosenbaum CA, Patel D, Smith EL, Korde N, Lu SX, Mailankody S, Shah UA, Lesokhin AM, Hassoun H, Tan C, Maura F, Derkach A, Diamond B, Rossi A, Pearse RN, Madduri D, Chari A, Kaminetzky D, Braunstein MJ, Gordillo C, Reshef R, Taur Y, Davies FE, Jagannath S, Niesvizky R, Lentzsch S, Morgan GJ, Landgren O. Hultcrantz M, et al. Among authors: patel d. Blood Cancer Discov. 2020 Jul 30;1(3):234-243. doi: 10.1158/2643-3230.BCD-20-0102. eCollection 2020 Nov. Blood Cancer Discov. 2020. PMID: 34651141 Free PMC article.
Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.
Hultcrantz M, Richter J, Rosenbaum CA, Patel D, Smith EL, Korde N, Lu SX, Mailankody S, Shah UA, Lesokhin AM, Hassoun H, Tan C, Maura F, Derkach A, Diamond B, Rossi A, Pearse R, Madduri D, Chari A, Kaminetzky D, Braunstein MJ, Gordillo C, Reshef R, Taur Y, Davies FE, Jagannath S, Niesvizky R, Lentzsch S, Morgan GJ, Landgren O. Hultcrantz M, et al. Among authors: patel d. Blood Cancer Discov. 2020 Nov 4;1(3):290. doi: 10.1158/2643-3230.BCD-20-0160. eCollection 2020 Nov. Blood Cancer Discov. 2020. PMID: 34661147 Free PMC article.
Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.
Shah UA, Maclachlan KH, Derkach A, Salcedo M, Barnett K, Caple J, Blaslov J, Tran L, Ciardiello A, Burge M, Shekarkhand T, Adintori P, Cross J, Pianko MJ, Hosszu K, McAvoy D, Mailankody S, Korde N, Hultcrantz M, Hassoun H, Tan CR, Lu SX, Patel D, Diamond B, Shah G, Scordo M, Lahoud O, Chung DJ, Landau H, Usmani SZ, Giralt S, Taur Y, Landgren CO, Block G, Block T, Peled JU, van den Brink MRM, Lesokhin AM. Shah UA, et al. Among authors: patel d. Clin Cancer Res. 2022 Dec 1;28(23):5149-5155. doi: 10.1158/1078-0432.CCR-22-0723. Clin Cancer Res. 2022. PMID: 36170461 Free PMC article.
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma.
Tan CR, Derkach A, Nemirovsky D, Ciardiello A, Diamond B, Hultcrantz M, Hassoun H, Mailankody S, Shah U, Maclachlan K, Patel D, Lahoud O, Landau H, Chung D, Shah G, Scordo M, Giralt S, Lesokhin A, Usmani S, Landgren O, Korde N. Tan CR, et al. Among authors: patel d. Res Sq [Preprint]. 2023 Feb 24:rs.3.rs-2583053. doi: 10.21203/rs.3.rs-2583053/v1. Res Sq. 2023. Update in: Blood Cancer J. 2023 Jul 25;13(1):112. doi: 10.1038/s41408-023-00882-y PMID: 36865246 Free PMC article. Updated. Preprint.
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
Tan CR, Derkach A, Nemirovsky D, Ciardiello A, Diamond B, Hultcrantz M, Hassoun H, Mailankody S, Shah U, Maclachlan K, Patel D, Lahoud OB, Landau HJ, Chung DJ, Shah GL, Scordo M, Giralt SA, Lesokhin A, Usmani SZ, Landgren O, Korde N. Tan CR, et al. Among authors: patel d. Blood Cancer J. 2023 Jul 25;13(1):112. doi: 10.1038/s41408-023-00882-y. Blood Cancer J. 2023. PMID: 37491332 Free PMC article.
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
Firestone RS, McAvoy D, Shekarkhand T, Serrano E, Hamadeh I, Wang A, Zhu M, Qin WG, Patel D, Tan CR, Hultcrantz M, Mailankody S, Hassoun H, Shah US, Korde N, Maclachlan KH, Landau HJ, Scordo M, Shah GL, Lahoud OB, Giralt S, Murata K, Hosszu KK, Chung DJ, Lesokhin AM, Usmani SZ. Firestone RS, et al. Among authors: patel d. Blood Adv. 2024 Apr 9;8(7):1600-1611. doi: 10.1182/bloodadvances.2023011225. Blood Adv. 2024. PMID: 37878808 Free PMC article.
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy.
Hamadeh IS, Shekarkhand T, Rueda C, Firestone RS, Wang AX, Korde N, Hultcrantz ML, Lesokhin AM, Mailankody S, Hassoun H, Shah UA, Maclachlan K, Rajeeve S, Patel D, Shah GL, Scordo M, Lahoud OB, Chung DJ, Landau HJ, Giralt S, Usmani SZ, Tan CR. Hamadeh IS, et al. Among authors: patel d. Blood Adv. 2024 Jun 25;8(12):3038-3044. doi: 10.1182/bloodadvances.2024012724. Blood Adv. 2024. PMID: 38598713 Free PMC article.
6,790 results